Document Detail


Assessment of benefits of a universal screen for maternal alcohol use during pregnancy.
MedLine Citation:
PMID:  20890939     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: The objective of this report is to estimate the benefits of universal meconium screening for maternal drinking during pregnancy. Fetal alcohol spectrum disorder (FASD), including its most severe manifestation fetal alcohol syndrome (FAS), is preventable and remains a public health tragedy. The incidences of FAS and FASD have been conservatively estimated to be 0.97 and 10 per 1000 births, respectively. Meconium testing has been demonstrated to be a promising at-birth method for detection of drinking during pregnancy.
METHODS: The current costs of FAS and FASD, alcohol treatment programs, and meconium screening were estimated by literature review. Monetary values were converted roughly to equal dollars in 2006.
RESULTS: Costs of adding meconium analysis to the current newborn screening program and of treatment for the identified mothers were estimated and compared to potential averted costs that may result from identification and intervention for mothers and affected infants. Three potential maternal treatment strategies are analyzed. Depending on the treatment type, the savings may range from $6 to $97 for every $1 spent on screening and treatment.
DISCUSSION: It needs to be emphasized, however, that such screening is premature and that to be effective this screening can be implemented only if there is a societal willingness to institute prevention and intervention programs to improve both women's and children's health. Future research should be directed at improving detection and developing in-depth prevention and remedial intervention programs. A thorough consideration of the ethical issues involved in such a screening program is also needed.
Authors:
Anne E Gifford; Kathleen J Farkas; Leila W Jackson; Christopher D Molteno; Joseph L Jacobson; Sandra W Jacobson; Cynthia F Bearer
Related Documents :
2480649 - Down's syndrome: current screening techniques.
6209839 - Ultrasound screening for structural defects in early pregnancy.
12768409 - Impact of public health strategies on the birth prevalence of cystic fibrosis in britta...
8942479 - The impact of routine obstetric ultrasonographic screening in a low-risk population.
24720599 - The impact of metabolic disease associated with metabolic syndrome on human pregnancy.
2094139 - One-stage ultrasound screening in pregnancy. an evaluation.
2196839 - Ultrasound investigation of fetal human upper respiratory anatomy.
12748509 - Intimate partner violence and adverse pregnancy outcomes: a population-based study.
9623639 - Allopregnanolone in women with premenstrual syndrome.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Birth defects research. Part A, Clinical and molecular teratology     Volume:  88     ISSN:  1542-0760     ISO Abbreviation:  Birth Defects Res. Part A Clin. Mol. Teratol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-25     Completed Date:  2011-02-04     Revised Date:  2013-08-22    
Medline Journal Info:
Nlm Unique ID:  101155107     Medline TA:  Birth Defects Res A Clin Mol Teratol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  838-46     Citation Subset:  IM    
Copyright Information:
© 2010 Wiley-Liss, Inc.
Affiliation:
International Society for Disease Surveillance, Boston, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alcohol Drinking / economics,  epidemiology*
Cohort Studies
Cost-Benefit Analysis*
Fatty Acids / analysis
Female
Fetal Alcohol Syndrome / diagnosis*,  economics
Humans
Infant, Newborn
Meconium*
Models, Economic
Neonatal Screening / economics*,  methods
Pregnancy
Grant Support
ID/Acronym/Agency:
P01 ES11261/ES/NIEHS NIH HHS; R01 AA016398/AA/NIAAA NIH HHS; R01 AA09524/AA/NIAAA NIH HHS; R01 AA16398/AA/NIAAA NIH HHS; R03 AA12618/AA/NIAAA NIH HHS; U01 AA014790/AA/NIAAA NIH HHS
Chemical
Reg. No./Substance:
0/Fatty Acids
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Preconception care for women with diabetes and prevention of major congenital malformations.
Next Document:  Primary care physician experience with children with oral clefts in three states.